Table 1.
Patient Baseline Characteristics
| Total (N=18) | |
|---|---|
| Dose Level (twice daily) | |
| 200 mg | 3 (16.7%) |
| 250 mg | 3 (16.7%) |
| 300 mg | 5 (27.8%) |
| 350 mg | 7 (38.9%) |
| Age (years) | |
| N | 18 |
| Mean (SD) | 59.1 (11.9) |
| Median | 62.5 |
| Q1, Q3 | 58.0, 67.0 |
| Range | (24.0–75.0) |
| Race | |
| White | 15 (83.3%) |
| Black or African American | 1 (5.6%) |
| American Indian or Alaska Native | 1 (5.6%) |
| Unknown: Patient unsure | 1 (5.6%) |
| Gender | |
| Female | 9 (50.0%) |
| Male | 9 (50.0%) |
| ECOG Performance Status | |
| 0 | 10 (55.6%) |
| 1 | 8 (44.4%) |
| Primary Tumor Site | |
| Hypopharynx | 5 (27.8%) |
| Larynx | 5 (27.8%) |
| Lip and oral cavity | 4 (22.2%) |
| Nasal cavity and ethmoid sinus | 1 (5.6%) |
| Oropharynx | 3 (16.7%) |